AR002270A1 - Clorhidrato de valaciclovir 2-[(2-amino-1,6-dihidro-6-oxo-9h-purin-9-il)metoxi]etil-l-valinato, uso para preparar un medicamento y proceso para obtener dicha forma cristalina - Google Patents

Clorhidrato de valaciclovir 2-[(2-amino-1,6-dihidro-6-oxo-9h-purin-9-il)metoxi]etil-l-valinato, uso para preparar un medicamento y proceso para obtener dicha forma cristalina

Info

Publication number
AR002270A1
AR002270A1 ARP960101082A AR10108296A AR002270A1 AR 002270 A1 AR002270 A1 AR 002270A1 AR P960101082 A ARP960101082 A AR P960101082A AR 10108296 A AR10108296 A AR 10108296A AR 002270 A1 AR002270 A1 AR 002270A1
Authority
AR
Argentina
Prior art keywords
purin
dihydro
oxo
ethyl
amino
Prior art date
Application number
ARP960101082A
Other languages
English (en)
Spanish (es)
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR002270(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of AR002270A1 publication Critical patent/AR002270A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
ARP960101082A 1995-01-20 1996-01-19 Clorhidrato de valaciclovir 2-[(2-amino-1,6-dihidro-6-oxo-9h-purin-9-il)metoxi]etil-l-valinato, uso para preparar un medicamento y proceso para obtener dicha forma cristalina AR002270A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative

Publications (1)

Publication Number Publication Date
AR002270A1 true AR002270A1 (es) 1998-03-11

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960101082A AR002270A1 (es) 1995-01-20 1996-01-19 Clorhidrato de valaciclovir 2-[(2-amino-1,6-dihidro-6-oxo-9h-purin-9-il)metoxi]etil-l-valinato, uso para preparar un medicamento y proceso para obtener dicha forma cristalina

Country Status (40)

Country Link
US (1) US6107302A (cs)
EP (1) EP0804436B1 (cs)
JP (1) JP3176633B2 (cs)
KR (1) KR100376074B1 (cs)
CN (1) CN1049893C (cs)
AP (1) AP662A (cs)
AR (1) AR002270A1 (cs)
AT (1) ATE302777T1 (cs)
AU (1) AU702794B2 (cs)
BG (1) BG63393B1 (cs)
BR (1) BR9606768A (cs)
CA (1) CA2210799C (cs)
CY (1) CY2531B1 (cs)
CZ (1) CZ297065B6 (cs)
DE (1) DE69635106T2 (cs)
DK (1) DK0804436T3 (cs)
EA (1) EA000364B1 (cs)
EE (1) EE03528B1 (cs)
ES (1) ES2248806T3 (cs)
FI (1) FI973063A7 (cs)
GB (1) GB9501178D0 (cs)
GE (1) GEP20001940B (cs)
HR (1) HRP960024B1 (cs)
HU (1) HU222993B1 (cs)
IL (1) IL116831A (cs)
IN (1) IN182468B (cs)
IS (1) IS2268B (cs)
NO (1) NO315558B1 (cs)
NZ (1) NZ298851A (cs)
OA (1) OA10499A (cs)
PL (1) PL182175B1 (cs)
RO (1) RO118693B1 (cs)
RS (1) RS49518B (cs)
SI (1) SI0804436T1 (cs)
SK (1) SK285329B6 (cs)
TR (1) TR199700656T1 (cs)
UA (1) UA46001C2 (cs)
UY (1) UY25779A1 (cs)
WO (1) WO1996022291A1 (cs)
ZA (1) ZA96449B (cs)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
ZA97400B (en) * 1996-01-19 1997-11-13 Glaxo Group Ltd Valaciclovir.
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
EP0976750A4 (en) * 1997-01-17 2001-05-30 Ajinomoto Kk NEW Z-VALACYCLOVIR CRYSTALS
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
SI1757606T1 (sl) * 2001-02-24 2009-10-31 Boehringer Ingelheim Pharma Ksantinski derivati za uporabo kot zdravila kot tudi postopek za njihovo pripravo
CN1551880A (zh) * 2001-09-07 2004-12-01 ������ҩ��ҵ���޹�˾ 阿昔洛韦缬氨酸酯盐酸盐的晶型
EP1453834A1 (en) * 2001-11-05 2004-09-08 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
EP1465894A4 (en) * 2001-11-14 2008-10-08 Teva Pharma SYNTHESIS AND PURIFICATION OF VALACYCLOVIR
AU2003240213A1 (en) * 2002-06-24 2004-01-06 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
CA2501557A1 (en) * 2002-10-16 2004-04-29 Teva Pharmaceutical Industries Ltd Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US20060229322A1 (en) * 2002-12-09 2006-10-12 Pau Cid Anhydrous crystalline form of valacyclovir hydrochloride
WO2004106338A1 (en) * 2003-05-30 2004-12-09 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
WO2005000850A2 (en) * 2003-06-02 2005-01-06 Teva Pharmaceutical Industries, Ltd. Novel crystalline forms of valacyclovir hydrochloride
JP2007522130A (ja) * 2004-01-21 2007-08-09 テバ ファーマシューティカル インダストリーズ リミティド 塩酸バラシクロビルの調製方法
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CN1976933A (zh) * 2004-06-30 2007-06-06 特瓦制药工业有限公司 减少晶体盐酸伐昔洛韦中的残留醇的方法
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
ATE546451T1 (de) * 2005-05-25 2012-03-15 Lilly Co Eli Cyclopropancarbonsäureester von acyclovir
EP1746098A1 (en) 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
JP5769966B2 (ja) * 2007-08-17 2015-08-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｆａｂ関連疾患治療用プリン誘導体
WO2009031576A1 (ja) * 2007-09-03 2009-03-12 Ajinomoto Co., Inc. バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
PE20140960A1 (es) * 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
WO2010018217A2 (en) * 2008-08-15 2010-02-18 Boehringer Ingelheim International Gmbh Organic compounds for wound healing
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
MX2011006713A (es) 2008-12-23 2011-07-13 Boehringer Ingelheim Int Formas salinas de compuesto organico.
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
CA2782179C (en) 2009-11-27 2020-06-23 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
EP2566469B1 (en) 2010-05-05 2022-12-21 Boehringer Ingelheim International GmbH Combination therapy
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
ES2953123T3 (es) 2010-06-24 2023-11-08 Boehringer Ingelheim Int Terapia para la diabetes
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
EP2852592A4 (en) * 2011-11-25 2015-12-23 Piramal Entpr Ltd PROCESS FOR THE PREPARATION OF VALACYCLOVIR CHLORHYDRATE
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849754B1 (en) 2012-05-14 2022-09-14 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
KR102391564B1 (ko) 2016-06-10 2022-04-29 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴 및 메트포르민의 병용물
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
US5831075A (en) * 1993-06-10 1998-11-03 Rolabo Sl Amino acid ester of nucleoside analogues
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
EP0804436A1 (en) 1997-11-05
HUP9801836A3 (en) 1999-06-28
WO1996022291A1 (en) 1996-07-25
ATE302777T1 (de) 2005-09-15
EA199700124A1 (ru) 1997-12-30
AU4453996A (en) 1996-08-07
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
IL116831A0 (en) 1996-05-14
MX9705462A (es) 1997-10-31
RS49518B (sr) 2006-10-27
KR19980701525A (ko) 1998-05-15
US6107302A (en) 2000-08-22
GEP20001940B (en) 2000-02-05
HRP960024A2 (en) 1997-10-31
EE03528B1 (et) 2001-10-15
AP9701058A0 (en) 1997-10-31
UY25779A1 (es) 2000-08-21
UA46001C2 (uk) 2002-05-15
AU702794B2 (en) 1999-03-04
NZ298851A (en) 1999-01-28
CA2210799A1 (en) 1996-07-25
CY2531B1 (en) 2006-04-12
BR9606768A (pt) 1997-12-30
HU222993B1 (hu) 2004-01-28
CZ297065B6 (cs) 2006-08-16
EA000364B1 (ru) 1999-06-24
ES2248806T3 (es) 2006-03-16
PL321326A1 (en) 1997-12-08
IN182468B (cs) 1999-04-17
IL116831A (en) 1998-10-30
FI973063A0 (fi) 1997-07-18
KR100376074B1 (ko) 2003-06-02
IS2268B (is) 2007-07-15
CA2210799C (en) 2008-06-10
EP0804436B1 (en) 2005-08-24
DK0804436T3 (da) 2005-12-27
EE9700175A (et) 1998-02-16
FI973063L (fi) 1997-09-18
YU3396A (sh) 1998-12-23
NO973326D0 (no) 1997-07-18
OA10499A (en) 2002-04-10
TR199700656T1 (xx) 1998-03-21
JPH11503718A (ja) 1999-03-30
BG101833A (bg) 1998-04-30
DE69635106T2 (de) 2006-06-08
NO973326L (no) 1997-09-16
DE69635106D1 (de) 2005-09-29
IS4527A (is) 1997-07-15
AP662A (en) 1998-08-19
HUP9801836A2 (hu) 1999-05-28
SK285329B6 (sk) 2006-11-03
HRP960024B1 (en) 2005-08-31
GB9501178D0 (en) 1995-03-08
PL182175B1 (pl) 2001-11-30
JP3176633B2 (ja) 2001-06-18
RO118693B1 (ro) 2003-09-30
FI973063A7 (fi) 1997-09-18
NO315558B1 (no) 2003-09-22
ZA96449B (en) 1996-08-07
CZ229497A3 (en) 1997-12-17
SI0804436T1 (sl) 2006-02-28
CN1179159A (zh) 1998-04-15
SK96597A3 (en) 1998-02-04

Similar Documents

Publication Publication Date Title
AR002270A1 (es) Clorhidrato de valaciclovir 2-[(2-amino-1,6-dihidro-6-oxo-9h-purin-9-il)metoxi]etil-l-valinato, uso para preparar un medicamento y proceso para obtener dicha forma cristalina
FI925737A7 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten indol-3-yylialkyylipiperatsiinijohdannaisten valmistamiseksi
SE9904505D0 (sv) Novel compounds
ITMI931714A0 (it) Uso del taxol per la produzione di un medicamento per il trattamento delle forme cancerose
FI914905L (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten merkaptoasetyyliamidopyrrolo- ja -pyridobentsatsepiinijohdannaisten valmistamiseksi
LT2003017A (en) Polymorphs of an epothilone analog
MY138352A (en) Benzothiazole derivatives
BR0017030A (pt) Derivados de tiazolilamida
GT199700052A (es) Sales metanosulfonatode5-(2-4-(1,2-benzoisotiazol-3-il)-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-onadihidratadas
ATE154880T1 (de) Multifunktionelle pharmazeutische verbindungen und verfahren zu ihrer verwendung
FI980862A0 (fi) Kiraalisia metyylifenyylioksatsolidinoneja
AR013079A1 (es) Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
FI931332A7 (fi) Uusia alkyleenidiammoniumdiklavulanaattijohdannaisia, menetelmä niidenvalmistamiseksi samoin kuin niiden käyttö kalvulaanihapon puhdistamiseksi
TR200000598T2 (tr) Kemik metabolizması bozukluklarının tedavisi için bir arginin mimetiği içeren peptitler, bunların üretimi ve sözkonusu bileşikleri içeren ilaçlar.
CA2046755A1 (en) /2r/-2-[di/2-propyl/phosphonylmethoxy]-3-p-toluenesulfonyloxy-1-trimethylacetoxypropane, its preparation and use
YU63696A (sh) Novi fenilamidin-derivati, postupci za njihovo pripremanje i njihova primena kao lekova
BR0013313A (pt) Derivados substituìdos de pirrolidino-2,3,4- triona-3-oxina eficazes como antagonistas de receptores de nmda
IL138288A0 (en) Process for the production of purine derivatives and intermediates thereof
ES2101747T3 (es) Penciclovir y famciclovir y derivados de guanina relacionados para el tratamiento de infecciones por vih-1.
MY127470A (en) Process for the synthesis of chloropurine intermediates
FI103202B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten 4-sulfonamido-1,4-dihydrokinoliiinijohdannaisten valmistamiseksi
FI905930A7 (fi) Menetelmä uusien, farmakologisesti käyttökelpoisten bispilokarpiinihapon esterijohdannaisten valmistamiseksi
ES2062214T3 (es) Derivados de aminooligohidroxi inhibidores de renina.
FI912733L (fi) Menetelmä terapeuttisesti käyttökelpoisten /(1-aryylipyrrolidin-2-yyli)metyyli/piperatsiinijohdannaisten valmistamiseksi
SE9704834D0 (sv) New process

Legal Events

Date Code Title Description
FC Refusal